Clinical safety profile of sotalol in patients with arrhythmias

Soyka, Lester F.; Wirtz, Carol; Spangenberg, Robert

doi:10.1016/0002-9149(90)90207-h

Cited by 140 publications

(61 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As discussed further below, antiarrhythmic drugs with QT interval prolonging potential carry a 1 to 3% risk of TdP over 1 to 2 years of exposure (Soyka et al, 1990;Hohnloser et al, 1995;Torp-Pedersen et al, 1999), with the exception of amiodarone. diLQTS also occurs with drugs not prescribed for cardiovascular indications, and the incidence seems orders of magnitude lower.…”

mentioning

confidence: 99%

Drug-Induced Long QT Syndrome

2010

View full text Add to dashboard Cite

mentioning

confidence: 99%

Drug-Induced Long QT Syndrome

2010

View full text Add to dashboard Cite

“…The incidence of Torsades de Pointes with both the acute intravenous form as well as the chronic oral route of amiodarone is quite rare (<2%). Torsades de Pointes, on the other hand, has been demonstrated to be quite common in patients receiving chronic oral sotalol (2-4%) [11][12][13] . This is primarily due to its effect on QTc prolongation.…”

Section: Discussionmentioning

confidence: 99%

Management of Atrial Fibrillation Post Bypass Surgery with Intravenous Sotalol: A Case Study

Cossú¹

2016

Journal of Atrial Fibrillation

View full text Add to dashboard Cite

“…Characteristics such as female gender, history of ventricular dysrhythmias and left ventricular dysfunction, greater magnitude of QT-interval prolongation, and hypokalemia increase the risk of TdP in patients given oral sotalol. 1,[17][18][19] If subgroups of included patients were described in sufficient detail, the characteristics of each subgroup were described.…”

Section: Methodsmentioning

confidence: 99%

“…Chronic oral administration of sotalol is associated with a 2-4% risk of torsades de pointes (TdP). [17][18][19] By definition, TdP occurs in association with a prolonged corrected QT (QTc) interval. Other factors that may contribute to its occurrence include an increase in inhomogeneity of repolarization, which may manifest SOTALOL Marill, Runge • IV SOTALOL AND TORSADES DE POINTES as increased dispersion of the QTc interval, [20][21][22] and the presence of early afterdepolarizations (EADs).…”

mentioning

confidence: 99%

Meta‐analysis of the Risk of Torsades de Pointes in Patients Treated with Intravenous Racemic Sotalol

Marill

Runge

2001

Academic Emergency Medicine

View full text Add to dashboard Cite

Abstract. Objective: Intravenous (IV) racemic sotalol is useful for the treatment of multiple tachydysrhythmias. The authors hypothesized that the risk of torsades de pointes (TdP) in patients treated with a single IV infusion of sotalol is lower than the 2-4% risk associated with chronic oral sotalol therapy. Methods: A MEDLINE search under the subject heading ''sotalol'' was made of all publications involving humans written in English or German from 1966 to October 1, 2000. A meta-analysis of all original reports including patients who were given a single infusion of at least 1.5 mg/kg or 100 mg of IV sotalol over 30 minutes or less was performed. Potential variables predictive of TdP were assessed. The primary outcome was the observation of TdP associated with IV sotalol infusion. Secondary measurements included hypotension, bradycardia, and worsening of congestive heart failure. All excluded studies and case reports were also examined for evidence of TdP associated with IV sotalol treatment. Results: The search included 1,005 publications. There were 37 reports in which 962 patients received IV sotalol and met the inclusion criteria. There was one report of self-terminating TdP lasting 10 seconds among the 962 patients included in the study. There was no report of TdP associated with only IV racemic sotalol administration in any of the excluded studies. If it is assumed that the risk of TdP is homogeneous in the population of patients treated with IV sotalol, then based on the 962 included patients, the rate of TdP is 0.1% (95% CI = 0.003% to 0.6%). Conclusions: The overall risk of TdP in patients treated with a single infusion of IV sotalol is low compared with that in patients given chronic oral sotalol therapy.

show abstract

Clinical safety profile of sotalol in patients with arrhythmias

Cited by 140 publications

References 19 publications

Drug-Induced Long QT Syndrome

Drug-Induced Long QT Syndrome

Management of Atrial Fibrillation Post Bypass Surgery with Intravenous Sotalol: A Case Study

Meta‐analysis of the Risk of Torsades de Pointes in Patients Treated with Intravenous Racemic Sotalol

Contact Info

Product

Resources

About